公开(公告)号：EP3149172A1

公开(公告)日：2017-04-05

申请号：EP15729289.7

申请日：2015-05-27

申请人： Quark Pharmaceuticals, Inc.

发明人： SQUIERS, Elizabeth C. ,  ERLICH, Shai ,  ROTHENSTEIN, Daniel ,  SHARON, Nir ,  ODENHEIMER, Daniel J. ,  FEINSTEIN, Elena

IPC分类号： C12N15/113 ,  A61K31/712

CPC分类号： C12N15/1135 ,  A61K9/0019 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/3515 ,  C12N2320/30 ,  C12N2310/3521

摘要： The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.

摘要翻译： 在一些实施方案中，本发明涉及用于预防器官中的局部缺血再灌注损伤（IRI）的化合物和方法，特别是涉及年龄在35岁及以上的器官中的IRI的化合物和方法。 具体用途包括在体内天然器官中预防IRI，在35岁及以上的供体器官的再植入和移植中。 另外的实施方案包括预防延迟移植物功能（DGF）以及减少受试者在接受死亡供体肾移植的频率，数量和持续时间。 该方法需要使体内或离体的器官与临时p53抑制剂接触。 还提供了新的临时dsNA p53抑制剂。

公开(公告)号：EP2958998A4

公开(公告)日：2016-07-13

申请号：EP14754069

申请日：2014-02-20

申请人： SIRNA THERAPEUTICS INC

发明人： CHANG WONSUK ,  GUIDRY ERIN N ,  STANTON MATTHEW G ,  ZEWGE DANIEL

IPC分类号： C12N15/11 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04

CPC分类号： C12N15/113 ,  C07H19/10 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/319

摘要： The present invention relates to RNAi molecules, and compositions thereof, comprising a 2′ internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5′ end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5′ modified nucleotides that comprise, among other potential modifications, a 2′ internucleoside linkage. The invention further relates to 5′ modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.

公开(公告)号：EP2195428A2

公开(公告)日：2010-06-16

申请号：EP08831316.8

申请日：2008-09-17

申请人： Applied Biosystems, LLC

发明人： PURI, Nitin ,  CHARLES, Irudaya ,  MAGDALENO, Susan ,  VLASSOV, Alexander ,  BURNETT, Chris

IPC分类号： C12N15/11

CPC分类号： C12N15/113 ,  C12N15/111 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/343 ,  C12N2320/53 ,  C12N2310/3521

摘要： Modification formats having modified nucleotides are provided for chemically synthesised RNA, in particular duplex RNA. RNA having modification formats and modified nucleotides provided herein reduce off-target effects in RNA interference of endogenous genes. Further modification formatted RNAs are demonstrated to be stabilized to nuclease-rich environments. Unexpectedly, increasing or maintaining strand bias, while necessary to maintain potency for endogenous RNA interference, is not sufficient for reducing off-target effects in cell biology assays.

公开(公告)号：EP2157182A2

公开(公告)日：2010-02-24

申请号：EP09008116.7

申请日：2006-03-08

申请人： Qiagen GmbH

发明人： Pitsch, Stefan ,  Muller, Evelyne ,  Reymond, Luc ,  Andreou, Ionna

IPC分类号： C12N15/113 ,  C07H21/00 ,  C07H19/04

CPC分类号： C12N15/111 ,  C07H19/04 ,  C07H19/10 ,  C07H19/20 ,  C07H21/00 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/318 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2320/51 ,  C12Y207/11024 ,  C12N2310/3521 ,  C12N2310/3525

摘要： The present invention pertains to a double-stranded siRNA molecule comprising a nucleotide modified at the 2'-position by a -O-CH 2 -O-(CH 2 ) 2 -OH group and related technologies.

摘要翻译： 本发明涉及包含通过-O-CH 2 -O-（CH 2）2 -OH基团在2位修饰的核苷酸的双链siRNA分子及相关技术。

公开(公告)号：EP2125852A1

公开(公告)日：2009-12-02

申请号：EP08729961.6

申请日：2008-02-15

申请人： Isis Pharmaceuticals, Inc.

发明人： MIGAWA, Michael, T. ,  SWAYZE, Eric, E. ,  BHAT, Balkrishen

IPC分类号： C07H19/06 ,  C07H19/16 ,  C07H21/00 ,  C12N15/11

CPC分类号： C07H19/06 ,  C07H19/16 ,  C07H21/00 ,  C12N15/111 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/341 ,  C12N2320/51 ,  C12N2310/3525

摘要： The present invention provides 5'-substituted-2'-F nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In one preferred embodiment the nucleoside analogs have either (R) or (5)-chirality at the 5'-position. These nucleoside analogs are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance.

公开(公告)号：EP1252307B1

公开(公告)日：2008-01-02

申请号：EP01903365.3

申请日：2001-01-26

申请人： Idera Pharmaceuticals, Inc.

发明人： AGRAWAL, Sudhir

IPC分类号： C12N15/11 ,  C07H21/00 ,  A61K31/7125

CPC分类号： C12N15/117 ,  A61K31/7125 ,  A61K2039/55561 ,  C12N2310/18 ,  C12N2310/31 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/319 ,  C12N2310/32

摘要： The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.

公开(公告)号：EP3234141A4

公开(公告)日：2018-06-20

申请号：EP15871104

申请日：2015-12-17

申请人： ALNYLAM PHARMACEUTICALS INC

发明人： JADHAV VASANT ,  MARAGANORE JOHN ,  MAIER MARTIN ,  RAJEEV KALLANTHOTTATHIL G ,  MANOHARAN MUTHIAH ,  AKINC AKIN ,  ZLATEV IVAN

IPC分类号： C12N15/113 ,  C12N15/11

CPC分类号： C12N15/111 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/3183 ,  C12N2310/319 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2310/322 ,  C12N2310/3533 ,  C12N2310/321 ,  C12N2310/3527 ,  C12N2310/3525 ,  C12N2310/3521

摘要： The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.

公开(公告)号：EP2125852B1

公开(公告)日：2016-04-06

申请号：EP08729961.6

申请日：2008-02-15

申请人： Ionis Pharmaceuticals, Inc.

发明人： MIGAWA, Michael, T. ,  SWAYZE, Eric, E. ,  BHAT, Balkrishen

IPC分类号： C07H19/06 ,  C07H19/16 ,  C07H21/00 ,  C12N15/11

CPC分类号： C07H19/06 ,  C07H19/16 ,  C07H21/00 ,  C12N15/111 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/341 ,  C12N2320/51 ,  C12N2310/3525

公开(公告)号：EP2958998A1

公开(公告)日：2015-12-30

申请号：EP14754069.4

申请日：2014-02-20

申请人： Sirna Therapeutics, Inc.

发明人： CHANG, Wonsuk ,  GUIDRY, Erin, N. ,  STANTON, Matthew, G. ,  ZEWGE, Daniel

IPC分类号： C12N15/11 ,  C07H21/04 ,  C07H21/02 ,  C07H21/00

CPC分类号： C12N15/113 ,  C07H19/10 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/319

摘要： The present invention relates to RNAi molecules, and compositions thereof, comprising a 2′ internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5′ end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5′ modified nucleotides that comprise, among other potential modifications, a 2′ internucleoside linkage. The invention further relates to 5′ modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.

摘要翻译： 本发明涉及RNAi分子及其组合物，其包含连接位置1的核苷酸和反义链5'末端的位置2的核苷酸的2'核苷酸键。 具体地，本发明涉及能够介导包含5'修饰的核苷酸的RNA干扰的单链和双链短干扰核酸（siNA）分子，其中包括2'核苷间键的其他潜在修饰。 本发明还涉及用作产生本发明的RNAi分子的试剂的5'修饰的核苷酸和使用所公开的RNAi分子的方法。

公开(公告)号：EP2895607A2

公开(公告)日：2015-07-22

申请号：EP13773450.5

申请日：2013-09-12

申请人： Quark Pharmaceuticals, Inc.

发明人： FEINSTEIN, Elena ,  AVKIN-NACHUM, Sharon ,  KALINSKI, Hagar ,  METT, Igor

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2320/30

摘要： The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.